Investment
Features
FeesSafety
Academy
More
Pluang+

Robert Kiyosaki links Bitcoin and AI to futurist Buckminster Fuller's predictions on wealth and work shifts.

Market News
14 Aug 2026
BeInCrypto
View Source
Neutral
pluang ai news

Robert Kiyosaki, author of Rich Dad Poor Dad, connected futurist Buckminster Fuller's ideas to the rise of Bitcoin and artificial intelligence (AI). Fuller, known for his innovative thinking on resource efficiency, influenced Kiyosaki's view that accelerating technology will reshape wealth and work. Despite Bitcoin trading 50% below its 2025 peak, Kiyosaki remains bullish, seeing it as a hedge against inflation and US debt, with a potential price target of $750,000 after a financial reset. He warns that employee mindsets risk AI replacement, while entrepreneurial thinking can leverage AI's growth. This perspective highlights a broader call to find purpose in serving others amid technological change.

More News

ICF International sees 24% stock upside with 2026 growth driven by energy, AI, and federal projects.

ICF International sees 24% stock upside with 2026 growth driven by energy, AI, and federal projects.

Analyst Barrington raised ICF International's price target to $110, suggesting a 24.45% upside from $88.39. The company expects 3% revenue growth and 5% non-GAAP EPS growth in 2026, fueled by energy, AI, and federal modernization efforts. Q2 2026 ear...

Analyst Insights
Bullish
1 hour ago
HSBC upgrades YPF to Buy on strong Q2 results and $51B LNG expansion plan

HSBC upgrades YPF to Buy on strong Q2 results and $51B LNG expansion plan

HSBC has upgraded YPF's rating to Buy following strong Q2 2026 results, including a 41.7% revenue increase to $6.57 billion and earnings per share of $3.07, surpassing estimates. YPF raised its 2026 adjusted EBITDA guidance to $8 billion and aims for...

Analyst Insights
Bullish
2 hours ago
Vivos Therapeutics beats Q2 EPS estimates but misses revenue, faces liquidity concerns.

Vivos Therapeutics beats Q2 EPS estimates but misses revenue, faces liquidity concerns.

Vivos Therapeutics reported Q2 2026 earnings per share of -$0.31, beating analyst expectations of -$0.42, but its revenue of $5.15 million fell short of the $5.63 million estimate. The company, focused on sleep apnea treatments, sees growing patient ...

Company Fundamentals
Neutral
2 hours ago
Major stocks fall sharply amid mixed earnings and negative outlooks, signaling broader market concerns.

Major stocks fall sharply amid mixed earnings and negative outlooks, signaling broader market concerns.

Several leading stocks, including SoundThinking, TSS, and ADI Global Distribution, dropped significantly due to factors like lowered revenue forecasts and disappointing quarterly results. SoundThinking fell over 25% after cutting its revenue outlook ...

Market News
Bearish
2 hours ago
Genasys Q3 revenue dips but gross margin jumps; analyst sees 108% stock gain potential

Genasys Q3 revenue dips but gross margin jumps; analyst sees 108% stock gain potential

Genasys reported a Q3 2026 revenue drop to $7.3M due to supply-chain issues and a work suspension, not demand loss. Despite this, gross margin improved to 57.1% and operating loss narrowed to $4M, showing better efficiency. An analyst raised the pric...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App